Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Status: Recruiting
Location: See all (17) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP\*) rare variant OR the TMEM43-p.S358L variant
• \*JUP carriers must be homozygous or compound heterozygous
• Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor
• Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening
Locations
Other Locations
Canada
University of Calgary
RECRUITING
Calgary
Nova Scotia Health
RECRUITING
Halifax
Hamilton General Hospital
RECRUITING
Hamilton
Kingston General Hospital
NOT_YET_RECRUITING
Kingston
London Health Sciences Centre
RECRUITING
London
Hopital du Sacré-Coeur de Montréal
NOT_YET_RECRUITING
Montreal
McGill University Health Centre
NOT_YET_RECRUITING
Montreal
Montreal Heart Institute
RECRUITING
Montreal
Newmarket Electrophysiologist Research Group 'NERG'
NOT_YET_RECRUITING
Newmarket
University of Ottawa Heart Institute
NOT_YET_RECRUITING
Ottawa
University Institute of Cardiology and Pneumology of Quebec
RECRUITING
Québec
Heart Health Institute Research Inc
RECRUITING
Scarborough Village
NL Health Services
RECRUITING
St. John's
St. Michael's Hospital
NOT_YET_RECRUITING
Toronto
Sunnybrook Health Sciences Centre
NOT_YET_RECRUITING
Toronto
University of British Columbia
RECRUITING
Vancouver
Victoria Cardiac Arrhythmia Trials Inc.
RECRUITING
Victoria
Contact Information
Primary
Jason Roberts, MD MAS
jason.roberts@phri.ca
905-521-2100
Backup
Maha Mushtaha
maha.mushtaha@phri.ca
Time Frame
Start Date: 2025-03-21
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 120
Treatments
Active_comparator: Tideglusib
Randomization to Tideglusib 1g po daily or matching placebo
Placebo_comparator: Placebo
Randomization to matching placebo 1g po daily
Related Therapeutic Areas
Sponsors
Collaborators: Canadian Institutes of Health Research (CIHR), Population Health Research Institute, Canadian SADS, Hearts in Rhythm Organization (HiRO), AMO Pharma Limited
Leads: Hamilton Health Sciences Corporation